SUDA announces the presentation of new data at the ASH Annual Meeting that support the use of SUDA’s anagrelide for the treatment of solid tumours.
PERTH, AUSTRALIA – 13 December 2017: SUDA Pharma (ASX: SUD), a leader in oro-mucosal drug delivery, announces the presentation of new data at the American Society of Haematology (ASH) Annual Meeting that support the use of SUDA’s anagrelide for the treatment of solid tumours.
The ASH Annual Meeting, which was held 9-12 December 2017 in Atlanta, Georgia, was the world’s largest haematology event with more than 25,000 attendees. The event highlighted the latest findings for the most relevant topics in haematology. On Saturday, 9 December 2017, there was a high-pro file session entitled New Innovations in Platelet Regulation of Tumour Growth and Metastasis.
The abstracts presented during the session included:
- Reciprocal Interactions Between Platelets and Metastatic Tumours
- Platelet and Megakaryocytic Regulation of Tumour Progression
- Role of Platelets in Adaptive Changes to Anti-Angiogenesis Therapy
It is recognised that platelets play an important role in the regulation of tumour growth and metastasis into the vascular space. The session at the ASH meeting included data from several key opinion leaders in the field, who presented on the underlying mechanisms by which the platelet-tumour interaction is mediated and how the reduction of platelets can help mediate tumour growth and metastasis. A better understanding of these complex mechanisms will aid in future development of anti-platelet and/or anti-metastatic therapies limiting tumour growth and extravasation.
SUDA recently acquired anagrelide, a potent anti-thrombotic agent used to reduce elevated levels of platelets. Anagrelide has the potential to be developed as an effective anti-cancer agent, but is fundamentally limited in its current oral formulation by cardio-stimulatory side-effects. SUDA is developing an oro-mucosal spray formulation of anagrelide that could minimise these side-effects by avoiding first-pass generation of a highly potent cardio-excitatory metabolite of the drug in the liver.
Mr Stephen Carter, SUDA’s CEO and Managing Director, commented: “The data presented at the prestigious ASH Annual Meeting provide further support for our rationale to acquire and develop an oro-mucosal spray of anagrelide as a novel anti-cancer therapy. There is strong evidence to suggest that platelets play an extremely important role in tumour growth. Anagrelide is a potent and selective inhibitor of platelets that is currently limited in its use by its route of administration. We believe there is substantial value in formulating this potentially powerful new anti-cancer agent with our OroMistÒ technology.”
Further information:
STEPHEN CARTER
CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR
SUDA Ltd
Tel: +61 8 6142 5555
Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
